Immunology Phase 3 Deal Benchmarks — Ex-US

Understanding Immunology Deal Benchmarks at Phase 3

Phase 3 Immunology licensing deals in Ex-US territory command a median upfront payment of $406M, with values ranging from $254M at the low end to $589M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the immunology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.1B to $2.0B, with a median of $1.6B. Royalty rates for immunology assets at this stage typically fall between 14.5% and 22.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.